Literature DB >> 29568118

The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates.

Eslam Mohamed1, Amir A Al-Khami2, Paulo C Rodriguez3.   

Abstract

Malignant cells upregulate distinct energy metabolism programs that support their proliferation, migration, and adaptation to the stressful tumor microenvironment (TME). Additionally, this exaggerated metabolic activity allows cancer cells to hijack essential nutrients and outcompete neighboring infiltrating immune cells, thereby impairing antitumor immunity. During recent years, there has been great interest in the field to understand the tumor-induced energy metabolism signals that regulate the function of immune cells in individuals with cancer. Accordingly, it is now well accepted that uncovering the mechanisms that instruct the metabolic behavior of cancer cells and tumor-associated immune cells is an indispensable strategy for the development of new approaches to overcome immune suppression in tumors. Thus, in this minireview, we briefly discuss the interaction between particular metabolic signaling pathways and immunosuppressive activity in different subsets of myeloid cells within the TME. Additionally, we illustrate potential central mechanisms controlling the metabolic reprogramming of myeloid cells in response to tumor-derived factors.

Entities:  

Keywords:  Tumor microenvironment; immune suppression; metabolic reprogramming; myeloid cells

Mesh:

Year:  2018        PMID: 29568118      PMCID: PMC6068094          DOI: 10.1038/s41423-018-0001-7

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  121 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

2.  Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Authors:  Nathalie Jacque; Anne Marie Ronchetti; Clément Larrue; Godelieve Meunier; Rudy Birsen; Lise Willems; Estelle Saland; Justine Decroocq; Thiago Trovati Maciel; Mireille Lambert; Laury Poulain; Marie Anne Hospital; Pierre Sujobert; Laure Joseph; Nicolas Chapuis; Catherine Lacombe; Ivan Cruz Moura; Susan Demo; Jean Emmanuel Sarry; Christian Recher; Patrick Mayeux; Jérôme Tamburini; Didier Bouscary
Journal:  Blood       Date:  2015-07-17       Impact factor: 22.113

3.  Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.

Authors:  Yu Zhu; John M Herndon; Dorothy K Sojka; Ki-Wook Kim; Brett L Knolhoff; Chong Zuo; Darren R Cullinan; Jingqin Luo; Audrey R Bearden; Kory J Lavine; Wayne M Yokoyama; William G Hawkins; Ryan C Fields; Gwendalyn J Randolph; David G DeNardo
Journal:  Immunity       Date:  2017-09-19       Impact factor: 31.745

Review 4.  Dendritic cell metabolism.

Authors:  Edward J Pearce; Bart Everts
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

5.  PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.

Authors:  Natasa Obermajer; Ravikumar Muthuswamy; Kunle Odunsi; Robert P Edwards; Pawel Kalinski
Journal:  Cancer Res       Date:  2011-10-24       Impact factor: 12.701

6.  Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation.

Authors:  Juan-Carlos Rodríguez-Prados; Paqui G Través; Jimena Cuenca; Daniel Rico; Julián Aragonés; Paloma Martín-Sanz; Marta Cascante; Lisardo Boscá
Journal:  J Immunol       Date:  2010-05-24       Impact factor: 5.422

7.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

8.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

Review 9.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

10.  Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study.

Authors:  Ji-Young Choe; Ji Yun Yun; Yoon Kyoung Jeon; Se Hoon Kim; Gyeongsin Park; Joo Ryoung Huh; Sohee Oh; Ji Eun Kim
Journal:  BMC Cancer       Date:  2014-05-15       Impact factor: 4.430

View more
  15 in total

1.  Mechanistic insights into cancer immunity and immunotherapy.

Authors:  Weiping Zou
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

2.  Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer.

Authors:  Alessio Ugolini; Vladimir A Tyurin; Yulia Y Tyurina; Evgenii N Tcyganov; Laxminarasimha Donthireddy; Valerian E Kagan; Dmitry I Gabrilovich; Filippo Veglia
Journal:  JCI Insight       Date:  2020-08-06

3.  The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.

Authors:  Eslam Mohamed; Rosa A Sierra; Jimena Trillo-Tinoco; Yu Cao; Patrick Innamarato; Kyle K Payne; Alvaro de Mingo Pulido; Jessica Mandula; Shuzhong Zhang; Paul Thevenot; Subir Biswas; Sarah K Abdalla; Tara Lee Costich; Kay Hänggi; Carmen M Anadon; Elsa R Flores; Eric B Haura; Shikhar Mehrotra; Shari Pilon-Thomas; Brian Ruffell; David H Munn; Juan R Cubillos-Ruiz; Jose R Conejo-Garcia; Paulo C Rodriguez
Journal:  Immunity       Date:  2020-04-14       Impact factor: 31.745

4.  Scinderin suppresses cell proliferation and predicts the poor prognosis of hepatocellular carcinoma.

Authors:  Bin Zhou; Tian-Wei Chen; Ya-Bo Jiang; Xu-Biao Wei; Chong-De Lu; Jing-Jing Li; Dong Xie; Shu-Qun Cheng
Journal:  Oncol Lett       Date:  2020-01-08       Impact factor: 2.967

Review 5.  Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.

Authors:  Robin Maximilian Awad; Yannick De Vlaeminck; Johannes Maebe; Cleo Goyvaerts; Karine Breckpot
Journal:  Front Immunol       Date:  2018-08-31       Impact factor: 7.561

Review 6.  Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor.

Authors:  Dehong Yan; Adeleye O Adeshakin; Meichen Xu; Lukman O Afolabi; Guizhong Zhang; Youhai H Chen; Xiaochun Wan
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

Review 7.  NK Cell Dysfunction and Checkpoint Immunotherapy.

Authors:  Jiacheng Bi; Zhigang Tian
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

8.  CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability.

Authors:  Xingzhe Ma; Liuling Xiao; Lintao Liu; Lingqun Ye; Pan Su; Enguang Bi; Qiang Wang; Maojie Yang; Jianfei Qian; Qing Yi
Journal:  Cell Metab       Date:  2021-03-09       Impact factor: 27.287

Review 9.  IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology.

Authors:  Hua-Xing Wei; Baolong Wang; Bofeng Li
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

10.  Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.

Authors:  Guoxu Zheng; Zhangyan Guo; Weimiao Li; Wenjin Xi; Baile Zuo; Rui Zhang; Weihong Wen; An-Gang Yang; Lintao Jia
Journal:  Signal Transduct Target Ther       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.